GMP Compliance in the Era of Advanced Therapies and Biologics

-

Navigating the New Frontier: GMP Compliance for ATMPs and Biologics

The global biopharmaceutical industry is undergoing a transformative shift as Advanced Therapy Medicinal Products (ATMPs)—including gene therapies, somatic cell therapies, and tissue-engineered products—and complex biologics become central to innovation pipelines. With over 1,900 active CGT clinical trials globally as of Q2 2025, according to a report by ARM, these living therapies offer unprecedented clinical benefits.


However, their unique nature presents a significant challenge: traditional Good Manufacturing Practice (GMP) frameworks, designed for stable, small molecule drugs, are often not directly applicable. Their development, manufacturing, and distribution demand a fundamentally different approach to compliance. often requiring specialized GMP compliance services.


The GMP Paradigm Shift for Living Products

What makes ATMPs and biologics so unique from a GMP perspective?


Living Products with Inherent Variability

Biologics and ATMPs are derived from living organisms, exhibiting natural variability. Even minor changes in process conditions can impact product identity, purity, and potency.


  • Implications: Establishing product consistency after manufacturing changes is crucial. This is where ICH Q5E comparability protocols become essential.


  • GMP Focus: This variability necessitates ultra-robust in-process controls, enhanced analytical characterization, and rigorous Critical Quality Attribute (CQA) monitoring throughout the entire process.

Strategy: Adopting New Compliance Roadmaps


Manufacturers and developers must adopt specific strategies to align their GMP practices with these evolving realities. Given the complexity and high stakes, many organizations are turning to external expertise:


  1. Expert Guidance: Firms often rely on specialized GMP compliance consulting services to navigate the highly intricate and constantly evolving global regulatory expectations for advanced therapies.

  2. Quality System Implementation: Implementing and maintaining the necessary quality infrastructure—from facility design to documentation—frequently requires external support through comprehensive GMP compliance services.

  3. Proactive Auditing: Before any regulatory inspection, engaging specialized GMP audit consultants is a critical step. These experts perform thorough gap analyses and mock inspections to ensure audit readiness and identify potential compliance risks unique to handling time-sensitive, patient-specific products


Comments

Post a Comment

Popular posts from this blog

What is an IMPD? Understanding Its Role in Clinical Trials and Drug Development

-
Image
What is an IMPD? Understanding Its Role in Clinical Trials and Drug Development An Investigational Medicinal Product Dossier (IMPD) is a key document in the clinical trial and drug development process, specifically for drugs or biologics undergoing testing in human clinical trials within the European Union (EU). It serves as a comprehensive report detailing the quality, manufacture, and control of the investigational product. The IMPD is a crucial regulatory submission required by the European Medicines Agency (EMA) or national regulatory bodies to evaluate whether a clinical trial can proceed. Key Components of an IMPD The IMPD includes several sections, providing information that ensures the safety and efficacy of the investigational product. These sections typically cover: Product Description and Composition: The IMPD provides detailed information about the investigational product, including its chemical composition, formulation, and dosage forms. Manufacturing and Control: This...
Read more

Quasi Drugs: Regulatory & Commercial Considerations for Japan and South Korea

-
Image
Navigating Quasi-Drug Regulations and Market Entry in Japan and South Korea In the dynamic Asia-Pacific market, quasi drugs represent a unique regulatory category that bridges the gap between cosmetics and pharmaceuticals . Particularly in Japan and South Korea, quasi drugs have gained traction for their hybrid benefits offering therapeutic claims while maintaining a relatively simpler regulatory pathway compared to full-fledged drugs.    Understanding the regulatory and commercial landscape of quasi drugs in these two key markets is essential for global companies aiming to enter or expand in East Asia. This article explores the updated guidelines, approval requirements, and commercialization opportunities for quasi drugs in Japan and South Korea.  What Are Quasi Drugs? Quasi drugs are defined as products that have mild pharmacological effects or physiological functions. They may not be as potent as traditional drugs, but they go beyond the scope of general cosmetics. Th...
Read more